Autologous Cell Therapy Market: Global Industry Analysis and Forecast (2021-2029) Trends, Statistics, Dynamics, Segmentation by Source, Application, End-use, and Region

Autologous Cell Therapy Market size was valued at USD 5.5 Bn. in 2021 and the total Autologous Cell Therapy revenue is expected to grow by 21.5 % from 2022 to 2029, reaching nearly USD 26.1 Bn.

Autologous Cell Therapy Market Overview:

Autologous cell therapy (ACT) is a novel therapeutic intervention in which an individual's cells are cultured and prolonged outside of the body before being reintroduced into the donor. The benefits of this approach include reduced risks from systemic immunological reactions, bio-incompatibility, and disease transmission associated with grafts or cells not cultivated from the individual. In the past decade, there has been a steady increase in studies of cell therapies for clinical use, with approximately 47 industry-sponsored clinical trials in pivotal or late stages using autologous cells. Autologous cell therapies involve extracting a cell sample from a patient, manipulating the cells, and then reinserting them into the patient. Such therapies have been shown to aid in tissue repair in a variety of therapeutic areas, including cardiovascular disease, peripheral arterial disease, liver disease, diabetes, neurodegenerative disorders, bone repair, and spinal cord injuries. These aspects are boosting the autologous cell therapy market. Autologous cell therapies are patient-specific, and large-scale production can be extremely challenging because each patient requires a separate batch. Companies frequently struggle to scale up production in clinically and commercially viable ways. Cell therapies are also frequently more dangerous to manufacture than most small-molecule pharmaceuticals. A mistake in the manufacturing of autologous cell therapy results in a failed treatment for a patient which is hampering the autologous cell therapy market. In addition, the often complex cell manufacturing process must adhere to both FDA regulations and the requirements of a viable business model. Companies are investigating the use of allogeneic cell therapies, which derive treatments or doses for multiple patients from a single donor's cells. This approach can help to improve manufacturing efficiency, potentially leading to cost savings. However, when using cell therapies derived from one donor in a different recipient, the risk of immune response and rejection must be considered. Autologous therapies use cells from the patient's own body, which virtually eliminates the risk of rejection. Moreover, allogeneic cells must be extensively cultured and cryopreserved for long-term storage. This prolonged culture raises the risk of cell transformation (e.g., tumorigenicity), and the frozen product frequently requires additional manipulation before administration. Autologous Cell Therapy Market To know about the Research Methodology :- Request Free Sample Report

Autologous Cell Therapy Market Dynamics:

Autologous Cell Therapy Market Drivers Growing number of diseases The prevalence of chronic diseases such as autoimmune diseases, cancer, blood disorders, and others is increasing. A rise in the number of people suffering from chronic diseases is also driving the autologous cell therapy market growth. MMR estimated the incidence of 38 cancers in 185 countries, there were an estimated 19,292,789 new cases of cancer diagnosed worldwide in 2020. Males accounted for 10,068,305 of the total diagnosed cancer cases, while females accounted for 9,229,484 cases. Male cancer cases were expected to reach 15,589,096 by 2040, while female cancer cases were expected to reach 13,310,846 by 2040. The increasing incidence of cancer among the global population is expected to drive market growth. Anemia, bleeding disorders such as hemophilia and blood clots, and blood cancers such as leukemia, lymphoma, and myeloma are examples of common chronic blood disorders. According to the Centers for Disease Control and Prevention's May 2022 update, sickle cell disease (SCD) affects approximately 100,000 Americans. It affects about 1 in every 365 Black or African American births. Effective treatment is the most effective way to save a patient's life who has a blood cell disorder. Other factors are also playing critical roles in boosting the autologous cell therapy market forward, including ongoing drug development for new applications, which are expected to further propel the autologous cell therapy market's growth. During the forecast period, the market will grow due to an increase in the number of clinical trials and an increase in the global adoption of cell therapies. Autologous Cell Therapy Market 1 Government support and initiatives With multiple government efforts and approvals to perform clinical studies of biomaterials, the stem cell treatment category is expected to grow at the quickest CAGR. According to the Organization for Economic Cooperation and Development (OECD), Denmark's average per capita healthcare spending in 2020 was around USD 5,600 Bn. Additionally, the Alzheimer Europe 2019 study indicates that the number of persons with dementia in Italy in 2018 was about 1,279,366 and that this figure is expected to quadruple to roughly 2,247,715 in 2050. Similarly, dementia will account for 4.13% of the general population in 2050, up from 2.12% in 2018. As the number of people suffering from dementia is predicted to increase in the near future, the autologous cell therapy market is likely to grow. A large number of research institutes, universities, and businesses from Europe, the United States, and Canada are also undertaking clinical studies for the use of stem cell-based therapeutics in nerve repair and regeneration. These countries are considered to have strong government support, a well-developed healthcare system, and a worldwide presence. As a result of the aforementioned factors, the category is expected to grow substantially during the forecast period.

Autologous Cell Therapy Market Restraints

Lack of Skilled Professionals Globally, there is a chronic shortage of skilled healthcare providers which hampers the autologous cell therapy market. India is dealing with serious shortages and unequal distributions of skilled healthcare personnel. According to the World Health Organization, around 28% of presently employed health professionals do not have the essential credentials. As the need for healthcare services grows and the sector embraces new technologies, there is a scarcity of personnel with digital skills, limiting their ability to manage nerve repair and regeneration technology. The Covid-19 pandemic has also demonstrated that healthcare resources committed to pandemic management in urban and rural regions compete directly with critical medical, surgical, interventional, and interventional diagnostic services for other disorders, such as neurological ailments. Autologous Cell Therapy Market Opportunity Increased Technological Advancement Government initiatives for cell therapy technology advancement and R&D were 46% in 2021 and 52% in 2021, which is driving the growth of the autologous cell therapy market. Furthermore, autologous anti-CD19 CAR T-cell therapy, such as Axicabtagene Ciloleucel, received FDA approval on April 1, 2022, for the treatment of adults with large B-cell lymphoma. Brexucabtagene autoleucel was approved by the Food and Drug Administration (FDA). In 2020, for the treatment of mantle cell lymphoma. These approvals expand the market opportunity for autologous cell therapy. Furthermore, these approvals for autologous cell therapy boost the market growth. Slowly progressive and degenerative neurological diseases like Parkinson's disease (PD) and Alzheimer's disease (AD) prompted the search for new treatments. In recent years, research has shifted toward transplant therapy for these diseases, as well as autologous cell therapy, which is emerging to alleviate symptoms and even reverse disease progression. Thus, technological advancements for decentralizing autologous cell therapy manufacturing are expected to significantly benefit the autologous cell therapy market forecast.

Autologous Cell Therapy Market Segment Analysis:

Based on Source, In terms of revenue, the bone marrow segment dominated the market in 2021, accounting for more than 46.9% of the market. According to sources, the autologous cell therapy market is divided into bone marrow, epidermis, mesenchymal stem cells, hematopoietic stem cells, chondrocytes, and others. Autologous cell therapy has successfully used bone marrow to treat various diseases. It is one of the main sources for cell therapy, where healthy stem cells from the patient's bone marrow or blood are collected and stored before treatment. Alternatively, autologous cell therapy with bone marrow has advantages over donor stem cells. Because of their preclinical and clinical applications in tissue regeneration and immune disease therapy, mesenchymal stem cells are expected to grow at the fastest rate during the forecast period. For example, Celltex Therapeutics Corporation announced in March 2020 that it has begun active discussions with the FDA about a study using MSCs to treat COVID-19 symptoms. Moreover, the company has investigated the safety and efficacy of using MSCs for patients suffering from injuries, pain, and maladies related to vascular, autoimmune, and other debilitating conditions such as inflammatory lung conditions, chronic obstructive pulmonary disease (COPD), and pneumonia. Based on the Application, In terms of revenue, the cancer segment dominated the autologous cell therapy market in 2021, with a share of more than 22.7%. The market is divided into cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, orthopedics, wound healing, and others. Cancer is expected to kill nearly 10 million people by 2020, according to the WHO. Autologous Cell Therapy Market 2MMR analyzed that there were 2.3 million new cancer cases diagnosed and 608,580 cancer deaths in the United States in 2021. With the growing burden of cases and demand for treatment and therapy, autologous cell therapy is expected to find its greatest demand in cancer applications. Anixa Biosciences announced in August 2022 that it had administered the first dose of its FSHR-targeted autologous cell therapy to an ovarian cancer patient in a Phase I trial. Autologous Cell Therapy Market 3Based on the End-use, In terms of revenue, hospitals and clinics dominated the autologous cell therapy market in 2021, accounting for more than 45.9% of the total. The market is divided into hospitals and clinics, ambulatory centers, academics and research, and others based on end-use. The rising prevalence of cancer, autoimmune diseases, cardiovascular disease, and neurodegenerative disorders has increased the demand for treatment and therapies. The academics & research segment is expected to witness growth at a CAGR of 21.8% over the estimated timeframe. Autologous cell therapy is garnering an increasing amount of interest worldwide and is being extensively studied. It is an emerging field of science that uses the living cellular to treat and prevent disease. Academics and research mostly conduct research in bone marrow, epidermis, mesenchymal stem cells, hematopoietic stem cells, and chondrocytes. For instance, in October 2022, Allogene Therapeutics mentioned the new survey of the U.S academic institutes that specialized in the administration of CAR T, which discovered 82.5% of respondents agreed that CAR T therapies have assisted in the management of cancers.

Autologous Cell Therapy Market 4Autologous Cell Therapy Market Regional Insights:

North America dominated the autologous cell therapy market in 2021, accounting for 41.9% of total revenue. The market in this region is highly competitive because most of the major market players, such as BrainStorm Cell Therapeutics and Bristol Myers Squibb, are present. Furthermore, the growing geriatric population, numerous immunological benefits, and the reduced risk of autologous cell therapy rejection have created new growth opportunities for the autologous cell therapy market. With rising disease burden, strong research activities in autologous cell therapies, the presence of a well-established biotechnology sector, developing healthcare facilities, and growing awareness for cell therapies, Asia Pacific is expected to grow at the fastest CAGR of 22.0% during the forecast period. For example, the Atara Biotherapeutics phase 1 clinical study was conducted in the company's collaboration with the University of Queensland and the QIMR Berghofer Medical Research Institute in November 2018. It describes outcomes in patients with progressive multiple sclerosis who received autologous EBV-specific T-cell immunotherapy from Atara.

Autologous Cell Therapy Market Scope: Inquiry Before Buying 

Autologous Cell Therapy Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2029
Historical Data: 2017 to 2021 Market Size in 2021: US$ 5.5 Bn.
Forecast Period 2022 to 2029 CAGR: 21.5% Market Size in 2029: US$ 26.1 Bn.
Segments Covered: by Source • Bone Marrow • Epidermis • Mesenchymal Stem Cells • Haematopoietic Stem Cells • Chondrocytes • Others
by Application • Cancer • Neurodegenerative Disorders • Cardiovascular Disorders • Autoimmune Disorders • Orthopedics • Wound Healing • Others
by End-use • Hospitals & Clinics • Ambulatory Centers • Academics & Research • Others

Autologous Cell Therapy Market by Region

• North America • Europe • Asia Pacific • South America • Middle East and Africa

Autologous Cell Therapy Market Key Players

• BrainStorm Cell Therapeutics (US) • Opexa Therapeutics (US) • Caladrius Biosciences Inc (US) • U.S. Stem Cell Inc (US) • Lonza (Switzerland) • Bristol Myers Squibb (US) • Corning Incorporated (US) • Vericel Corporation (US) • Catalent, Inc (US) • Lineage Cell Therapeutics Inc. (US) • Castle Creek Biosciences Inc (US) • Sangamo Therapeutics (US) • Novartis (Switzerland) • Holostem Terapie Avanzate S.R.L (Italy) • Pharmicell Co. Inc (Korea) • Tego Science (South Korea) • Autolus therapeutics (UK) • Bio Elpida (France) • Bayer AG (Germany) • Sartorius AG (Germany) • Daiichi Sankyo Co., Ltd (Japan) • Takeda Pharmaceutical Company Limited (Japan) • Sumitomo Chemical Co., Ltd (Japan) • Regeneus Ltd. (Australia) Frequently Asked Questions: 1] What segments are covered in the Global Autologous Cell Therapy Market report? Ans. The segments covered in the Autologous Cell Therapy Market report are based on Source, Application, End-use, and Region. 2] Which region is expected to hold the highest share in the Global Autologous Cell Therapy Market? Ans. The North America region is expected to hold the highest share of the Autologous Cell Therapy Market. 3] What is the market size of the Global Autologous Cell Therapy Market by 2029? Ans. The market size of the Autologous Cell Therapy Market by 2029 is expected to reach US$ 26.1 Bn. 4] What is the forecast period for the Global Autologous Cell Therapy Market? Ans. The forecast period for the Autologous Cell Therapy Market is 2021-2029. 5] What was the market size of the Global Autologous Cell Therapy Market in 2021? Ans. The market size of the Autologous Cell Therapy Market in 2021 was valued at US$ 5.5 Bn.
1. Global Autologous Cell Therapy Market Size: Research Methodology 2. Global Autologous Cell Therapy Market Size: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global Autologous Cell Therapy Market Size 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Autologous Cell Therapy Market Size: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • Middle East and Africa • South America 3.12. COVID-19 Impact 4. Global Autologous Cell Therapy Market Size Segmentation 4.1. Global Autologous Cell Therapy Market Size, by Source (2021-2029) • Bone Marrow • Epidermis • Mesenchymal Stem Cells • Haematopoietic Stem Cells • Chondrocytes • Others 4.2. Global Autologous Cell Therapy Market Size, by Application (2021-2029) • Cancer • Neurodegenerative Disorders • Cardiovascular Disorders • Autoimmune Disorders • Orthopedics • Wound Healing • Others 4.3. Global Autologous Cell Therapy Market Size, by End-use (2021-2029) • Hospitals & Clinics • Ambulatory Centers • Academics & Research • Others 5. North America Autologous Cell Therapy Market (2021-2029) 5.1. North America Autologous Cell Therapy Market Size, by Source (2021-2029) • Bone Marrow • Epidermis • Mesenchymal Stem Cells • Haematopoietic Stem Cells • Chondrocytes • Others 5.2. North America Autologous Cell Therapy Market Size, by Application (2021-2029) • Cancer • Neurodegenerative Disorders • Cardiovascular Disorders • Autoimmune Disorders • Orthopedics • Wound Healing • Others 5.3. North America Autologous Cell Therapy Market Size, by End-use (2021-2029) • Hospitals & Clinics • Ambulatory Centers • Academics & Research • Others 5.4. North America Semiconductor Memory Market, by Country (2021-2029) • United States • Canada • Mexico 6. European Autologous Cell Therapy Market (2021-2029) 6.1. European Autologous Cell Therapy Market, by Source (2021-2029) 6.2. European Autologous Cell Therapy Market, by Application (2021-2029) 6.3. European Autologous Cell Therapy Market, by End-use (2021-2029) 6.4. European Autologous Cell Therapy Market, by Country (2021-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Autologous Cell Therapy Market (2021-2029) 7.1. Asia Pacific Autologous Cell Therapy Market, by Source (2021-2029) 7.2. Asia Pacific Autologous Cell Therapy Market, by Application (2021-2029) 7.3. Asia Pacific Autologous Cell Therapy Market, by End-use (2021-2029) 7.4. Asia Pacific Autologous Cell Therapy Market, by Country (2021-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Autologous Cell Therapy Market (2021-2029) 8.1. Middle East and Africa Autologous Cell Therapy Market, by Source (2021-2029) 8.2. Middle East and Africa Autologous Cell Therapy Market, by Application (2021-2029) 8.3. Middle East and Africa Autologous Cell Therapy Market, by End-use (2021-2029) 8.4. Middle East and Africa Autologous Cell Therapy Market, by Country (2021-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Autologous Cell Therapy Market (2021-2029) 9.1. South America Autologous Cell Therapy Market, by Source (2021-2029) 9.2. South America Autologous Cell Therapy Market, by Application (2021-2029) 9.3. South America Autologous Cell Therapy Market, by End-use (2021-2029) 9.4. South America Autologous Cell Therapy Market, by Country (2021-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1. BrainStorm Cell Therapeutics (US) 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Opexa Therapeutics (US) 10.3. Caladrius Biosciences Inc (US) 10.4. U.S. Stem Cell Inc (US) 10.5. Lonza (Switzerland) 10.6. Bristol Myers Squibb (US) 10.7. Corning Incorporated (US) 10.8. Vericel Corporation (US) 10.9. Catalent, Inc (US) 10.10. Lineage Cell Therapeutics Inc. (US) 10.11. Castle Creek Biosciences Inc (US) 10.12. Sangamo Therapeutics (US) 10.13. Novartis (Switzerland) 10.14. Holostem Terapie Avanzate S.R.L (Italy) 10.15. Pharmicell Co. Inc (Korea) 10.16. Tego Science (South Korea) 10.17. Autolus therapeutics (UK) 10.18. Bio Elpida (France) 10.19. Bayer AG (Germany) 10.20. Sartorius AG (Germany) 10.21. Daiichi Sankyo Co., Ltd (Japan) 10.22. Takeda Pharmaceutical Company Limited (Japan) 10.23. Sumitomo Chemical Co., Ltd (Japan) 10.24. Regeneus Ltd. (Australia)

About This Report

Report ID 171125
Category Healthcare
Published Date Jan 2023
Updated Date
Contact Us